Subfoveal choroidal thickness in idiopathic choroidal neovascularization and treatment outcomes after intravitreal bevacizumab therapy

Hyesun Kim, Kahyun Lee, Christopher Seungkyu Lee, Suk Ho Byeon, Sungchul Lee

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: To determine subfoveal choroidal thickness in idiopathic choroidal neovascularization (CNV) and evaluate visual and anatomical outcomes in patients with idiopathic CNV after intravitreal bevacizumab. Methods: Retrospective observation case series. Seventeen eyes of 17 patients with idiopathic CNV were treated with a single intravitreal bevacizumab injection, followed by additional doses based on optical coherence tomography findings, including intraretinal fluid, subretinal fluid, or pigment epithelial detachment. We analyzed best-corrected visual acuity, central subfield thickness, and subfoveal choroidal thickness at presentation and final visit. Seventeen unaffected fellow eyes and 17 healthy eyes constituted the control group for subfoveal choroidal thickness. Results: The subfoveal choroidal thickness was significantly thinner in eyes with idiopathic CNV (237.59 ± 53.84 m) than in the unaffected fellow eyes (281.71 ± 59.01 m, P =0.001) or normal control eyes (290.38 ± 58.94 m, P= 0.028). Mean logarithm of the minimum angle of resolution best-corrected visual acuity improved from 0.46 initially to 0.26 after treatment (P =0.024). Mean central subfield thickness decreased from 387.88 ± 97.52 m at baseline to 261.41 ± 31.18 m after treatment (P < 0.001). Conclusion: Subfoveal choroidal thickness is reduced and may be associated with the pathophysiology of idiopathic CNV. Intravitreal bevacizumab resulted in significant visual and anatomical improvement in patients with idiopathic CNV.

Original languageEnglish
Pages (from-to)481-486
Number of pages6
JournalRetina
Volume35
Issue number3
DOIs
Publication statusPublished - 2015 Mar 10

Fingerprint

Choroidal Neovascularization
Visual Acuity
Therapeutics
Subretinal Fluid
Intravitreal Injections
Optical Coherence Tomography
Bevacizumab
Observation
Control Groups

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Kim, Hyesun ; Lee, Kahyun ; Lee, Christopher Seungkyu ; Byeon, Suk Ho ; Lee, Sungchul. / Subfoveal choroidal thickness in idiopathic choroidal neovascularization and treatment outcomes after intravitreal bevacizumab therapy. In: Retina. 2015 ; Vol. 35, No. 3. pp. 481-486.
@article{dc9868ae16fc47e2a1e480480b0b75df,
title = "Subfoveal choroidal thickness in idiopathic choroidal neovascularization and treatment outcomes after intravitreal bevacizumab therapy",
abstract = "Purpose: To determine subfoveal choroidal thickness in idiopathic choroidal neovascularization (CNV) and evaluate visual and anatomical outcomes in patients with idiopathic CNV after intravitreal bevacizumab. Methods: Retrospective observation case series. Seventeen eyes of 17 patients with idiopathic CNV were treated with a single intravitreal bevacizumab injection, followed by additional doses based on optical coherence tomography findings, including intraretinal fluid, subretinal fluid, or pigment epithelial detachment. We analyzed best-corrected visual acuity, central subfield thickness, and subfoveal choroidal thickness at presentation and final visit. Seventeen unaffected fellow eyes and 17 healthy eyes constituted the control group for subfoveal choroidal thickness. Results: The subfoveal choroidal thickness was significantly thinner in eyes with idiopathic CNV (237.59 ± 53.84 m) than in the unaffected fellow eyes (281.71 ± 59.01 m, P =0.001) or normal control eyes (290.38 ± 58.94 m, P= 0.028). Mean logarithm of the minimum angle of resolution best-corrected visual acuity improved from 0.46 initially to 0.26 after treatment (P =0.024). Mean central subfield thickness decreased from 387.88 ± 97.52 m at baseline to 261.41 ± 31.18 m after treatment (P < 0.001). Conclusion: Subfoveal choroidal thickness is reduced and may be associated with the pathophysiology of idiopathic CNV. Intravitreal bevacizumab resulted in significant visual and anatomical improvement in patients with idiopathic CNV.",
author = "Hyesun Kim and Kahyun Lee and Lee, {Christopher Seungkyu} and Byeon, {Suk Ho} and Sungchul Lee",
year = "2015",
month = "3",
day = "10",
doi = "10.1097/IAE.0000000000000354",
language = "English",
volume = "35",
pages = "481--486",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

Subfoveal choroidal thickness in idiopathic choroidal neovascularization and treatment outcomes after intravitreal bevacizumab therapy. / Kim, Hyesun; Lee, Kahyun; Lee, Christopher Seungkyu; Byeon, Suk Ho; Lee, Sungchul.

In: Retina, Vol. 35, No. 3, 10.03.2015, p. 481-486.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Subfoveal choroidal thickness in idiopathic choroidal neovascularization and treatment outcomes after intravitreal bevacizumab therapy

AU - Kim, Hyesun

AU - Lee, Kahyun

AU - Lee, Christopher Seungkyu

AU - Byeon, Suk Ho

AU - Lee, Sungchul

PY - 2015/3/10

Y1 - 2015/3/10

N2 - Purpose: To determine subfoveal choroidal thickness in idiopathic choroidal neovascularization (CNV) and evaluate visual and anatomical outcomes in patients with idiopathic CNV after intravitreal bevacizumab. Methods: Retrospective observation case series. Seventeen eyes of 17 patients with idiopathic CNV were treated with a single intravitreal bevacizumab injection, followed by additional doses based on optical coherence tomography findings, including intraretinal fluid, subretinal fluid, or pigment epithelial detachment. We analyzed best-corrected visual acuity, central subfield thickness, and subfoveal choroidal thickness at presentation and final visit. Seventeen unaffected fellow eyes and 17 healthy eyes constituted the control group for subfoveal choroidal thickness. Results: The subfoveal choroidal thickness was significantly thinner in eyes with idiopathic CNV (237.59 ± 53.84 m) than in the unaffected fellow eyes (281.71 ± 59.01 m, P =0.001) or normal control eyes (290.38 ± 58.94 m, P= 0.028). Mean logarithm of the minimum angle of resolution best-corrected visual acuity improved from 0.46 initially to 0.26 after treatment (P =0.024). Mean central subfield thickness decreased from 387.88 ± 97.52 m at baseline to 261.41 ± 31.18 m after treatment (P < 0.001). Conclusion: Subfoveal choroidal thickness is reduced and may be associated with the pathophysiology of idiopathic CNV. Intravitreal bevacizumab resulted in significant visual and anatomical improvement in patients with idiopathic CNV.

AB - Purpose: To determine subfoveal choroidal thickness in idiopathic choroidal neovascularization (CNV) and evaluate visual and anatomical outcomes in patients with idiopathic CNV after intravitreal bevacizumab. Methods: Retrospective observation case series. Seventeen eyes of 17 patients with idiopathic CNV were treated with a single intravitreal bevacizumab injection, followed by additional doses based on optical coherence tomography findings, including intraretinal fluid, subretinal fluid, or pigment epithelial detachment. We analyzed best-corrected visual acuity, central subfield thickness, and subfoveal choroidal thickness at presentation and final visit. Seventeen unaffected fellow eyes and 17 healthy eyes constituted the control group for subfoveal choroidal thickness. Results: The subfoveal choroidal thickness was significantly thinner in eyes with idiopathic CNV (237.59 ± 53.84 m) than in the unaffected fellow eyes (281.71 ± 59.01 m, P =0.001) or normal control eyes (290.38 ± 58.94 m, P= 0.028). Mean logarithm of the minimum angle of resolution best-corrected visual acuity improved from 0.46 initially to 0.26 after treatment (P =0.024). Mean central subfield thickness decreased from 387.88 ± 97.52 m at baseline to 261.41 ± 31.18 m after treatment (P < 0.001). Conclusion: Subfoveal choroidal thickness is reduced and may be associated with the pathophysiology of idiopathic CNV. Intravitreal bevacizumab resulted in significant visual and anatomical improvement in patients with idiopathic CNV.

UR - http://www.scopus.com/inward/record.url?scp=84924438669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924438669&partnerID=8YFLogxK

U2 - 10.1097/IAE.0000000000000354

DO - 10.1097/IAE.0000000000000354

M3 - Article

VL - 35

SP - 481

EP - 486

JO - Retina

JF - Retina

SN - 0275-004X

IS - 3

ER -